VialTirzepatide 30 mg vial
Dual-agonist weight research
Investigated for combined GIP and GLP-1 signaling.
- Ships from Canada in 1–2 business days
- Free shipping over $120
Place your order, then send the e-Transfer. We pack it as soon as it arrives.
For research use only. Not for human consumption.
Complete your setup
Needles and wipes are free. Water is $19.
- Bacteriostatic Water
$19.00 · To reconstitute the powder
- Needles
Free · For reconstitution
- Alcohol Wipes
Free · To prep the vial stopper
Compare. Side by side, from the research.
About Tirzepatide
Tirzepatide is studied as a dual agonist at the GIP and GLP-1 receptors. Research examines whether combining the two incretin pathways differs from GLP-1 agonism alone.
How it works
- Dual Incretin
- Studied at both GIP and GLP-1 receptors, the GIP component distinguishing it from single agonists.
- Metabolic Signaling
- Explored for effects across glucose handling and appetite regulation together.
What you need
- Bacteriostatic Water
- Needles
- Alcohol Wipes
- A protocol guide comes with every order
Shipping & payment
- Packed and dispatched within 1–2 business days
- Delivered across Canada in 2–5 business days, tracked
- Temperature-controlled packaging where the product needs it
- Free shipping on orders over $120
- Prices in CAD · pay by Interac e-Transfer
- Format
- Lyophilised powder in a sealed vial
- Strength
- 30 mg per vial
- Storage
- Refrigerate, away from light. Once reconstituted, keep refrigerated and use within the window on the insert.
- Reconstitution
- 2 mL bacteriostatic water for this 30 mg vial (15 mg/mL)
- Route in research
- Subcutaneous
- Target
- GLP-1R / GIPR
- SKU
- TR30
Handling
- 1ReconstituteAdd bacteriostatic water down the side of the vial. Swirl, never shake. Agitation damages the peptide chain.
- 2StoreRefrigerate at 2–8°C once mixed. Reconstituted peptide is stable for the window given in your protocol guide.
- 3Measure with the calculator Use an insulin syringe at the units your protocol specifies. Rotate sites and log what you take.
- Purity
- High-performance liquid chromatography (HPLC), by an independent laboratory
- Identity
- Mass spectrometry, on the same batch
- How often
- Every batch
- COA
- The certificate of analysis is matched to the lot code printed on your vial
- Evidence
- Late clinical
Check your lot
Every vial carries a lot code. Enter it, or scan the QR on the label, to see its expiry and certificate of analysis.
Late clinicalTirzepatide has been evaluated in multiple randomized phase 3 trials, including SURPASS-1, SURPASS-2 against semaglutide, and SURMOUNT-4, with phase 2 work in liver disease and a cardiovascular outcomes trial also underway.
What research examines
- Glycemic control in type 2 diabetes trials
- Weight reduction and weight maintenance in adults with obesity
- Appetite, energy intake, and fat mass
- Head-to-head comparison with semaglutide
- Metabolic dysfunction-associated steatohepatitis with liver fibrosis
- Cardiovascular outcomes compared with dulaglutide
Reported in studies
- Safety was a primary focus of phase 3 trials such as SURPASS-1, though specific adverse event rates are not summarized here
- Cardiovascular safety is being assessed against dulaglutide in the SURPASS-CVOT trial
- Studied for effects on gastric emptying as part of its mechanism
- Long-term safety outside controlled trial settings is not characterized in this overview
Published research protocols
2.5 mg, 1/week, am fasted
Research protocols have used 1.5–15 mg per administration, once weekly (morning, fasted), stepping up from 2.5 mg to 10 mg by week 13. Reported cycle: continuous until target weight loss.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Measure with the calculatorCoreX AI
Ask about Tirzepatide
Plain answers, from the basics to the studies.
Research information, not medical advice.
Often researched with Tirzepatide
Vial
Vial
Vial
FAQ
Questions, answered
Tirzepatide is a peptide studied as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Research examines whether engaging both incretin pathways produces effects that differ from GLP-1 agonism alone. It has been evaluated in large randomized clinical trials in type 2 diabetes and obesity, and in smaller trials exploring liver disease and cardiovascular outcomes.
Tirzepatide is studied at both the GIP and GLP-1 receptors, and its GIP activity distinguishes it from single-receptor GLP-1 agonists. Research has explored its combined effects on insulin signaling, gastric emptying, and satiety. Mechanistic work published in JCI Insight described it as an imbalanced and biased dual agonist, meaning its activity at the two receptors and their downstream signaling pathways is not equivalent.
Phase 3 trials have examined glycemic control in type 2 diabetes, including SURPASS-1 and a head-to-head comparison with semaglutide. The SURMOUNT-4 trial studied continued use for maintenance of weight reduction in adults with obesity, and a later trial compared it with semaglutide for obesity. Other studies have examined appetite, energy intake, and fat mass, liver fibrosis in steatohepatitis, and cardiovascular events versus dulaglutide.
Safety was assessed alongside efficacy in phase 3 trials such as SURPASS-1, and cardiovascular safety is being evaluated against dulaglutide in the SURPASS-CVOT trial. Specific adverse event types and rates are not summarized in this overview. Because the compound acts on gastric emptying as part of its studied mechanism, gastrointestinal effects are an area of research attention. Researchers should consult the primary trial publications for detailed safety findings.
Research protocols have used 1.5 to 15 mg per administration, given subcutaneously once weekly (morning, fasted), stepping up from 2.5 mg to 10 mg by week 13. The reported cycle was continuous until target weight loss. These figures describe what published protocols have used and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference.
You may also like
Vial · Pen
Vial
Vial
Vial
Vial
Vial

